Access World-Class, No-Nonsense Expertise to Launch Your Clinical Trial

30-40%

Cost savings compared to traditional CROS

90 Days or Less

The goal for SSU

Why Work with Winniedel

At Winniedel, we work every day to position new biotech and biopharma sponsors and researchers with a diverse, global network of cancer centers available and willing to be your study’s next clinical trial site. We focus on SSU for Early Phase (FIH-2b) oncology trials, while also providing productive site sourcing “temp checks” to gauge site interest in your asset.

Winniedel in-house implementation and planning expertise with streamlined systems to deliver faster oncology outcomes

Global Oncology Site Universe

Existing business unit with 250+ sites, a therapeutically aligned global KOL network, and agile vendor partners

Winniedel Oncology CRO building reliable partnerships to deliver study needs without costly change orders

Expert Planning & In-House Implementation

Solutions to accelerate results and proven processes and systems in place.

Winniedel global oncology site universe with 250+ study sites, aligned KOL network, and vendor partner support

Partnerships & Relationships

Partnerships with oncology-focused smaller CROs that are less expensive, dependable, and driven to meet study needs after SSU. No change order revolving doors.

Our One-of-a-Kind Approach to Clinical Trial Launch


  • Expert Planning and In-House Implementation

    We offer innovative solutions and “white glove” services that accelerate results. Our proven SSU optimization model and methods guide a collaborative and efficient approach to SSU.

  • Relationship-Focused Model for Efficiency

    We believe in the power of real, lasting relationships, and that has allowed us to build trust with cancer centers worldwide that are willing and available to be matched with your study.  

  • Access to the Global Oncology Site Universe

    Our global network will be at your fingertips; we offer access to 250+ study sites, therapeutically aligned global KOL network, and agile vendor partners worldwide.

  • Cost-Effective Collaboration with Partners

    We have established partnerships with oncology-focused smaller CROs that are less expensive, dependable, and driven to meet study needs and timelines after SSU.

  • Diverse Patient Populations Worldwide

    Through our global and diversified network of sites, we strive to facilitate oncological and precision medicine research that captures all subjects across diverse patient types. 

The Global Oncology Site Universe

 Unlock our worldwide network of over 250+ clinical oncology trial sites in 28 countries.

Diversity, inclusivity, and meeting timelines are our strengths.

Map of Winniedel global oncology site universe with 250+ clinical trial sites across 28 countries supporting diverse patients

The Global Oncology Site Universe (GOSU) is a network of exemplary oncology clinical trial sites that Winnidel has unfettered access to through decades of building trusting, real, and human relationships across cancer centers globally.  The GOSU is built on the philosophy that battling cancer involves a profoundly compassionate and human touch: our GOSU includes both.

We can match your trial to appropriate, high-quality, and willing trial sites within 24 to 48 hours, on average. Trial sites available through the GOSU include academic, interdisciplinary network (IDN), and community-based trial sites. Depending on what the needs of your study are, we can connect you overnight to the appropriate trial sites and patient populations.

We offer trial sites located in:

  • United States of America, Canada, Mexico, United Kingdom, European Union, Eastern EU, India, Central and South America, Africa and Australia

Winniedel oncology CRO services including KOL engagement, site management, SSU activities, and precision medicine trial support

Services Breakdown

In addition to our one-of-a-kind approach and world-class expertise, we offer the following concrete services

All SSU activities, including site sourcing and procurement

KOL/PI engagement 

Site management during SSU and throughout the duration of the study

We’re in it for the long haul. We have the commitment and capabilities to launch complex oncological and precision medicine trials and keep them running via our reliable CRO partnerships.

Standard CROs Can’t Help New Developers Keep Pace with Biotech and Pharma

Other CROs

  • Utilize database subscriptions to find trial sites = minimal understanding of cababilities/limitations

  • Lack of systems to support sites with staffing and other challenges

  • Don’t know what they don’t know about early phase oncology trials

  • Not focused on SSU excellence

  • History of rescues during SSU

  • Emerging/small biotechs are little fish in a big pond

  • Excessive use of change orders

Winniedel

  • Procure sites from curated and personalized network, giving unknown developers better credibility for trial slots

  • Experts in early-phase cancer trials, including radiopharma

  • Network of KOLs supports proactive planning for protocol challenges

  • “White glove” service and transparency

  • Commitment and processes focused on SSU success

  • Biotechs are placing trust in WINNIEDEL with their SSU

  • Parnterships with smaller innovative CROs for a seamless transition from SSU to the maintenance phase of the study

  • We mean what we say, we say what we mean. No revolving change order doors

Expect More with Winniedel Oncology

Average 24–48 hour response rates for oncology study sites contacted through Winniedel’s GOSU network

Response rates in 24-48 hours on average for study sites contacted through GOSU

Winniedel oncology CRO consistently achieving clinical trial site procurement goals across all studies

Site procurement goals reached for every trial

Asset viability assessments conducted through GOSU oncology clinical trial site network

Of GOSU sites contacted to determine asset viability

Oncology clinical trial success rates showing high risk of failure from Phase 1 and 2 through Phase 3 toward commercialization

Oncology Developers Face a High Risk of Commercialization Failure

Winniedel helps decrease commercialization failure because we focus on doing things right the first time. We decrease costs and timelines while focusing on quality and getting treatment options to patients faster.

Aligning Proven Sites to the Right Clinical Trial

Winniedel oncology CRO aligning global KOLs and clinical trial sites to support precision medicine and early phase studies

Facilitates effective Study Start-Up.

Dependable enrollment and strong site engagement

Commitment and capabilities to run complex oncological precision medicine trials

Global Network of Exemplary KOLS and Oncology Clinical Trial Sites

Optimized relationship-focused model for efficient and productive site sourcing and procurement Early Phase (FIH-2b) trial focus

What People are Saying About Winniedel

  • Dr. Tandy Tipps is an exceptional collaborator whose insight and dedication consistently elevates the life sciences industry's work. Her approach to advancing healthcare is both visionary and deeply rooted in patient needs, making every project together impactful and inspiring. It’s a privilege to partner with someone who shares GLSA's commitment to excellence and innovation.

    Denise McNerney, Partner at Global Life Sciences Alliance (GLSA)

  • No one knows the sites in the early phase oncology space better than Dr. Tandy Tipps including their areas of therapeutic expertise and where they are actively seeking trials to fit their patients’ needs. In a time where we are seeing overall start-up timelines increase, she can move mountains and help navigate the nuances of site start-up so we can get sites open quicker for enrollment.

    Megan Liles, VP, Clinical Delivery, HGI Clinical

  • I've worked with Tandy on early-phase trials for over six years. She is integrity-driven, honest, and deeply committed to building strong relationships. As a proven expert in expedited SSU, her close ties with PIs and cancer centers worldwide enable precise trial-to-site matching. Tandy founded WINNIEDEL to put the focus back on cancer patients who need potentially life-saving treatment options faster.

    Glen Weiss, MD, Biotech Executive & Medical Oncologist*

    *Unpaid consultant to WINNIEDEL

Get Started Today.

We're here to help you get results—without the fluff and without wasting your time. At Winnidell Oncology, we believe in transparency, straight answers, and delivering exactly what you need to drive your project forward. If you’re looking for a partner who keeps things real and works as hard as you do, you’re in the right place.